Sandoz, a key player in generic and biosimilar medicines, on Wednesday announced the launch of Tyruko (natalizumab) in Germany from February 1. Developed by Polpharma Biologics, Tyruko is the first and only biosimilar to treat RRMS, the company said in a statement.
According to the biosimilar maker, Tyruko is indicated as a single disease-modifying therapy (DMT) in adults with highly active RRMS. This is the same indication as approved by the European Commission for reference medicine Tysabri.
Early treatment with disease-modifying therapies can have a significant impact on people living with multiple sclerosis and their potential future disabilities. As the first and only biosimilar in this space, the availability of Tyruko is a crucial milestone in improving access to effective and safe therapies for those in Europe that need them most,” Rebecca Guntern, President Europe, Sandoz
